View SRRA stock info; drug pipeline; latest news; SEC filings; articles; 2020 Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call. Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it 23 Jan 2020 Sierra Oncology, Inc. (NASDAQ:SRRA) stock increased by 3638.9% to by PiperJaffray, on January 03, is at Overweight, with a price target of Stocks. Data delayed by at least 15 min. Overview. United States. Americas. Europe. Asia PAC. Middle East & Africa Name, Price, Change This is available for NSE and BSE Indices & Stock charts only. * Please Note: The Intraday price data is close to real-time and doesn't capture all traded ticks. Get the latest stock technical analysis of stock/share trends, BSE/NSE technical chart, live market map and more technical stock information at Moneycontrol. Technical analysis focuses on market action — specifically, volume and price. Technical analysis is only one approach to analyzing stocks. When considering
SRRA - Sierra Oncology Stock Barchart Opinion - Barchart.com
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a … SIERRA ONCOLOGY, INC. : SRRA Stock Price | MarketScreener Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in … Sierra Oncology, Inc. (SRRA) Stock: What You Should Know ... Mar 01, 2019 · When it comes to SRRA, the short percent of the float is 0.60%. The Action That We’ve Seen Over the Past Year. The past year has been an exciting one for Sierra Oncology, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.05 – 3.70.
Jan 22, 2020 · Nano cap Sierra Oncology (NASDAQ:SRRA) slumps 16% premarket on increased volume in reaction to its planned 1:40 reverse split of its common stock …
View live SIERRA ONCOLOGY INC chart to track its stock's price action. Find market predictions, SRRA financials and market news. Highs/Lows(14), -0.2114, Sell. Ultimate Oscillator, 48.210, Sell. ROC, -4.390, Sell . Bull/Bear Power(13), -0.4740, Sell. Buy: 1. Sell: 6. Neutral: 1. Summary:Strong SRRA investment & stock information. Get the latest ProNAi Therapeutics, Inc. SRRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Learn about SRRA with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a Stock Style. Large-Cap 10 Jan 2020 In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has
Sierra Oncology Inc (SRRA) Stock Analysis | Morningstar
Pronai Therapeutics, Inc. - SRRA - Stock Price Today - Zacks View ProNAi Therapeutics, Inc. SRRA investment & stock information. Get the latest ProNAi Therapeutics, Inc. SRRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. SRRA Sierra Oncology, Inc. Common Stock - NASDAQ.com Sierra Oncology, Inc. Common Stock (SRRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Sierra Oncology, Inc. (SRRA) stock price, quote, history ...
Sierra Oncology, Inc. (SRRA) Stock Price, Quote, History ... Find the latest Sierra Oncology, Inc. (SRRA) stock quote, history, news and other vital information to help you with your stock trading and investing.
NASDAQ:SRRA Sierra Oncology, Inc. Stock Analysis - CapitalCube SRRA-US's earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA). SRRA - Research and Analysis for SIERRA ONCOLOGY, INC ... In-depth view of key statistics and finances for SIERRA ONCOLOGY, INC. (SRRA) on MSN Money. $SRRA Stock Technical Analysis | Sierra Oncology ... Nov 06, 2019 · SRRA closed down 7.42 percent on Friday, April 3, 2020, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.